<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Ciliary neurotrophic factor (CNTF) improves metabolic variables of <z:mp ids='MP_0001261'>obese</z:mp> animals with characteristics of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, mainly by reducing <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated whether CNTF was able to improve other metabolic variables in mouse models of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, such as beta cell mass and insulin clearance, and whether CNTF has any effect on non-<z:mp ids='MP_0001261'>obese</z:mp> mice with characteristics of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Neonatal mice were treated with 0.1 mg/kg CNTF or <z:chebi fb="2" ids="50744">citrate</z:chebi> buffer via intraperitoneal injections, before injection of 250 mg/kg alloxan </plain></SENT>
<SENT sid="3" pm="."><plain>HEPG2 cells were cultured for 3 days in the presence of <z:chebi fb="2" ids="50744">citrate</z:chebi> buffer, 1 nmol/l CNTF or 50 mmol/l alloxan or a combination of CNTF and alloxan </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-one days after treatment, we determined body weight, epididymal fat weight, blood <z:chebi fb="105" ids="17234">glucose</z:chebi>, plasma insulin, NEFA, <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, insulin clearance and beta cell mass </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, we assessed insulin receptor and protein kinase B phosphorylation in peripheral organs, as well as insulin-degrading enzyme (IDE) protein production and alternative splicing in the liver and HEPG2 cells </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: CNTF improved insulin sensitivity and beta cell mass, while reducing <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion and insulin clearance in Swiss mice, improving <z:chebi fb="105" ids="17234">glucose</z:chebi> handling in a non-<z:mp ids='MP_0001261'>obese</z:mp> type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> model </plain></SENT>
<SENT sid="7" pm="."><plain>This effect was associated with lower IDE production and activity in liver cells </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> these effects were observed even at 21 days after CNTF treatment </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: CNTF protection against type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is partially independent of the anti-<z:hpo ids='HP_0001513'>obesity</z:hpo> actions of CNTF, requiring a reduction in insulin clearance and increased beta cell mass, besides <z:mp ids='MP_0002891'>increased insulin sensitivity</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, knowledge of the long-term effects of CNTF expands its pharmacological relevance </plain></SENT>
</text></document>